MedNexus
2019年 · 第99卷第02期
MedNexus
- 全部
- 专家论坛
- 标准与规范
- 肺癌诊治
- 临床研究
- 基础研究
- 新技术新方法
- 病例报告
- 综述
- 国内外学术动态
- 更正
Primary carnitine deficiency (PCD), also known as primary carnitine malabsorption (CUD), or carnitine transport disorder (CTD), is a disease in which high-affinity sodium-dependent carnitine transporter (OCTN2) protein function is defective due to SLC22A5 gene mutation, increased carnitine excretion in urine, and carnitine deficiency in blood, tissues and cells, thus causing defect in fatty acid β oxidation. There were clear ethnic differences in the prevalence of PCD. The reported prevalence in the United States ranged from 1 in 20 000 to 70 000[
The information of the member units of the expert group in the article "Expert Consensus of Anlotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer" in Volume 98, Issue 44, 2018 is incorrectly laid out, and the correction is as follows: Zhou Jianying (Department of Respiratory Medicine, the First Affiliated Hospital of Zhejiang University); Zhao Qiong (Department of Thoracic Oncology, Hangzhou Cancer Hospital). Apologies to both experts!
本期目次

